Fate Therapeutics, Inc. · NASDAQ:FATE
Fate Therapeutics — ASGCT Annual Meeting 2026
13 slides from Fate Therapeutics's conference presentation, May 14, 2026
Slide 1: FT839: A Multi-Antigen Targeting Off-the-Shelf Dual-CAR T Cell for Autoimmune Diseases
MAKING CELL THERAPIES ACCESSIBLE TO ALLTM FT839: A Multi-Antigen Targeting Off-the-Shelf Dual-CAR T Cell for the Treatment of Pathogenic B and T Cells in Autoimmune Diseases ASGCT Annual Meeting May 14th, 2026 Mark Jelcic, PhD
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the safety and therapeutic potential of the Company’s product candidates, the advancement of and plans and tim
Slide 3: What Good Is a Cure That No One Can Access?
What Good Is a Cure That No One Can Access? Autologous CAR T-cell therapy is transformative, but is unattainable for most patients ✓ “Living drugs”: CAR T cells have revolutionized how autoimmune diseases can be treated However, Autologous CAR T-cell therapies… • Cost ~$400,000 - $600,000+ per patie
Slide 4: Outpatient Enabled & Community Delivered CAR T Cells
Outpatient Enabled & Community Delivered CAR T Cells FT819: First CAR T-cell therapy in autoimmune delivered without hospital stay ✓ Successful dosing of FT819 in an outpatient setting • Same-day discharge → No hospitalization and extended observation ✓ Broad patient access • Elimination of inpatien
Slide 5: iPSC Platform: An 'Off-the-Shelf' Cell Therapy Solution
iPSC Platform: An ‘Off-the-Shelf’ Cell Therapy Solution Mass produced, multiplex-engineered cell products for on-demand patient treatment Consistent Off-the-shelf Master cell Gene editing is Master cell bank is manufacture drug product iPSC → any bank contains a one-time starting material results in
Slide 6: Targeting CD19 Alone is Not Enough for Eliminating Complex Multicellular Diseases
Targeting CD19 Alone is Not Enough for Eliminating Complex Multicellular Diseases Targeting B-lineage (CD19) and activated immune cells (CD38) for a comprehensive immune reset Autoimmune diseases are driven by multiple immune cell types • T cells can independently sustain disease (e.g., Multiple Scl
Slide 7: FT839: Off-the-Shelf Anti-CD19/CD38 Dual CAR T-Cell Product Candidate
FT839: Off-the-Shelf Anti-CD19/CD38 Dual CAR T-Cell Product Candidate ADR-armed CAR T cells target select immune cell subsets to unlock multi-disease therapy potential Multi-Antigen Targeting Multi-Antigen Comprehensive targeting of pathogenic immune cells Targeting • CD19 CAR: Targets B-cell lineag
Slide 8: FT839 Broadly Eliminates Aberrant Immune Cell Types
FT839 Broadly Eliminates Aberrant Immune Cell Types CD19 and CD38 CARs selectively eliminate B lineage cells and activated T cells Possible FT839 Disease Indications PBMC Co-Culture Assay Nervous Multiple Sclerosis (MS) CD19 Expression CD38 Expression System • CD4+ T cells Day 0 CD8+ T CD8+ T 10⁶ Au
Slide 9: Sword & Shield ‒ Eliminating Conditioning Chemotherapy
Sword & Shield ‒ Eliminating Conditioning Chemotherapy ADR and CD58KO selectively restrict the generation and activation of alloreactive immune cells Eliminate Reactive Immune Cells Shield Reactive Immune Cell Interactions CD58 KO Allo Defense CD58 Null Receptor (ADR) Sword & ShieldTM ADR eliminates
Slide 10: FT839 Maintains Comprehensive Disease Activity in Allo-settings
FT839 Maintains Comprehensive Disease Activity in Allo-settings Selective depletion of B cells and activated immune cells while preventing emergence of alloreactive T cells Rheumatoid Arthritis PBMCs Sword and Shield prevents the emergence of alloreactive T cells PBMC Populations CD38 Expression All
Slide 11: Multi-antigen Targeting in Combination with T Cell Engagers and mAbs
Multi-antigen Targeting in Combination with T Cell Engagers and mAbs Customizable pairing with clinically approved biologics extends disease cell targeting capabilities CD3FR: CD3ε fusion receptor hnCD16: high affinity, non-cleavable CD16a Enables combination with TCEs without a TCR Enables synergis
Slide 12: Delivering Off-the-Shelf CAR T Cells Without Conditioning Chemotherapy
Delivering Off-the-Shelf CAR T Cells to Patients Without Conditioning Chemotherapy in Autoimmune, Hematological Malignancies and Solid Tumor Settings FT819 in Autoimmune Disease FT836 armed with Sword and Shield in Solid Tumors CD19-targeting CAR T cells combined with SOC therapy MICA/B-targeting CA
Slide 13: Acknowledgements
Acknowledgements Key Collaborators • Alex Garcia • Karina Palomares • Shilpi Chandra • Loraine Campanati • Michel Sadelain • Karl-Johan Malmberg • Soheila Shirinbak • Carissa Dege • Maksim Mamonkin • Brian Groff • Pei-Fang Tsai • Alan Williams • Tom Lee • Alma Gutierrez • Natalie Shiff • Miguel Meza